Top-Line Data Show Lyrica Met Primary Endpoint in Clinical Trial as Adjunctive Therapy versus Levetiracetam in Patients with Partial Onset Seizures

Thu Feb 21, 2013 8:00am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130221:nBw215261a

NEW YORK--(Business Wire)--
Pfizer Inc. (NYSE: PFE) today announced top-line results for a Phase 3 study
that showed Lyrica® (pregabalin) Capsules CV were as effective as levetiracetam
as an adjunctive therapy in adult epilepsy patients experiencing refractory
partial onset seizures. 

The top-line results indicate that the study met its primary endpoint by
demonstrating that a comparable proportion of patients on Lyrica achieved at
least a 50 percent reduction in the 28-day seizure rate during the maintenance
phase relative to levetiracetam. The adverse event profile in the study was
consistent with that known for Lyrica. 

Epilepsy is a chronic disorder in which seizures occur intermittently. Partial
onset seizures (simple, complex, and secondarily generalized tonic-clonic) are
the most common, particularly in adults, and often require more than one
antiepileptic medication. Patients with refractory partial onset seizures are
those patients whose seizures are not completely controlled by medical
treatment. 

About the Study

The study was a randomized, double-blind, parallel-group, multicenter,
comparative, flexible-dose study to compare Lyrica (300, 450, 600 mg/day) to
levetiracetam (1,000, 2,000, 3,000 mg/day) in reducing partial onset seizure
frequency in subjects with epilepsy. 

Subjects included in the study were diagnosed with epilepsy with partial onset
seizures for at least two years, and were unresponsive to treatment with at
least two but no more than five prior antiepileptic drugs (AEDs) and, at the
time of the study enrollment, were on stable dosages of one or two standard
AEDs. 

The primary efficacy endpoint was the responder rate, defined as the proportion
of subjects who had at least a 50 percent reduction in the 28 day seizure rate
(all partial seizures) during the 12-week maintenance phase, as measured from
the 6-week baseline. 

The most common adverse events reported in Lyrica-treated patients were
headache, dizziness, insomnia, somnolence, nausea and fatigue. The most common
adverse events reported for levetiracetam treated patients were somnolence,
dizziness and headache. 

Results from this study will be submitted for presentation at upcoming
scientific congresses and for publication in a peer-reviewed medical journal. 

About Lyrica

Lyrica is currently approved for various indications in 120 countries and
regions globally. 

In the U.S., Lyrica has been approved by the Food and Drug Administration for
five indications. Lyrica was initially approved for partial onset seizures in
adults with epilepsy who take one or more drugs for seizures. In 2007, Lyrica
became the first FDA-approved treatment for the management of fibromyalgia.
Other indications include neuropathic pain associated with diabetic peripheral
neuropathy, post-herpetic neuralgia (pain after shingles) and the management of
neuropathic pain associated with spinal cord injury (for which Lyrica became the
first FDA- approved treatment in 2012). Lyrica`s ongoing clinical development
program is focused on the significant unmet needs of patients with certain
chronic pain conditions. 

In the European Union, Lyrica is approved for four indications: peripheral and
central neuropathic pain, generalized anxiety disorder in adults, and partial
seizures with or without secondary generalization in adults with epilepsy. 

In Japan, Lyrica is the only treatment approved for all three of the following
indications: post-herpetic neuralgia, neuropathic pain and pain associated with
fibromyalgia. 

Antiepileptic drugs (AEDs), including Lyrica, increase the risk of suicidal
thoughts or behavior in patients taking AEDs for any indication. There have been
post-marketing reports of angioedema and hypersensitivity with Lyrica. Treatment
with Lyrica may cause dizziness, somnolence, dry mouth, edema and blurred
vision. Other most common adverse reactions include weight gain, constipation,
euphoric mood, balance disorder, increased appetite and thinking abnormal
(primarily difficulty with concentration/attention). 

For Lyrica prescribing information in the United States visit www.lyrica.com, in
the European Union visit www.ema.europa.eu/ema and in Japan visit
www.pfizer.co.jp. 

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to improve health and
well-being at every stage of life. We strive to set the standard for quality,
safety and value in the discovery, development and manufacturing of medicines
for people and animals. Our diversified global health care portfolio includes
human and animal biologic and small molecule medicines and vaccines, and many of
the world's best-known consumer products. Every day, Pfizer colleagues work
across developed and emerging markets to advance wellness, prevention,
treatments and cures that challenge the most feared diseases of our time.
Consistent with our responsibility as the world's leading biopharmaceutical
company, we also collaborate with health care providers, governments and local
communities to support and expand access to reliable, affordable health care
around the world. For more than 150 years, Pfizer has worked to make a
difference for all who rely on us. To learn more about our commitments, please
visit us at www.pfizer.com.

Pfizer Inc.
Media:
Jennifer Kokell, 212-733-2596
or
Investors:
Suzanne Harnett, 212-733-8009 



Copyright Business Wire 2013